Radiation Oncology (Nov 2011)

Impact of pathological tumor stage for salvage radiotherapy after radical prostatectomy in patients with prostate-specific antigen < 1.0 ng/ml

  • Umezawa Rei,
  • Ariga Hisanori,
  • Ogawa Yoshihiro,
  • Jingu Keiichi,
  • Matsushita Haruo,
  • Takeda Ken,
  • Fujimoto Keisuke,
  • Sakayauchi Toru,
  • Sugawara Toshiyuki,
  • Kubozono Masaki,
  • Narazaki Kakutaro,
  • Shimizu Eiji,
  • Takai Yoshihiro,
  • Yamada Shogo

DOI
https://doi.org/10.1186/1748-717X-6-150
Journal volume & issue
Vol. 6, no. 1
p. 150

Abstract

Read online

Abstract Background To evaluate prognostic factors in salvage radiotherapy (RT) for patients with pre-RT prostate-specific antigen (PSA) Methods Between January 2000 and December 2009, 102 patients underwent salvage RT for biochemical failure after radical prostatectomy (RP). Re-failure of PSA after salvage RT was defined as a serum PSA value of 0.2 ng/ml or more above the postradiotherapy nadir followed by another higher value, a continued rise in serum PSA despite salvage RT, or initiation of systemic therapy after completion of salvage RT. Biochemical relapse-free survival (bRFS) was estimated using the Kaplan-Meier method. Multivariate analysis was performed using the Cox proportional hazards regression model. Results The median follow-up period was 44 months (range, 11-103 months). Forty-three patients experienced PSA re-failure after salvage RT. The 4-year bRFS was 50.9% (95% confidence interval [95% CI]: 39.4-62.5%). In the log-rank test, pT3-4 (p Conclusions In patients who have received salvage RT after RP with PSA

Keywords